Advertisement

Topics

"AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit" Drugs and Medication Database

19:20 EDT 20th June 2019 | BioPortfolio

Here are the most relevant "AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit" Drugs and Medications that we have found in our database.

More Information about "AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit" on BioPortfolio

We have published hundreds of AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit news stories on BioPortfolio along with dozens of AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit Clinical Trials and PubMed Articles about AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit Companies in our database. You can also find out about relevant AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit Drugs and Medications on this site too.

Showing "AbbVie Announces Depatuxizumab Mafodotin Fails Demonstrate Survival Benefit" Drugs and Medications, all 22

Possibly Relevant

Paricalcitol [amneal pharmaceuticals llc]

These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively. see full prescribing information for PARICALCITOL CAPSULES. PARICALCITOL capsules, for oral use.Initial U.S. Approval: 1998

Paricalcitol [bionpharma inc.]

These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively. See full prescribing information for PARICALCITOL CAPSULES. PARICALCITOL capsules, for oral use Initial U.S. Approval: 1998

Paricalcitol [aurobindo pharma limited]

These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively. See full prescribing information for PARICALCITOL CAPSULES. PARICALCITOL capsules, for oral use Initial U.S. Approval: 1998

Paricalcitol [marksans pharma limited]

These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively. See Full Prescribing Information for PARICALCITOL CAPSULES. PARICALCITOL capsules, for oral use Initial U.S. Approval:1998

Paricalcitol [dr. reddy's laboratories limited]

These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively. See full prescribing information for PARICALCITOL CAPSULES . PARICALCITOL capsules, for oral use Initial U.S. Approval: 1998

K-tab [abbvie inc.]

These highlights do not include all the information needed to use K-TAB safely and effectively. See full prescribing information for K-TAB. K-TAB (potassium chloride) extended-release tablets, for oral useInitial U.S. Approval: 1948

Moderiba [abbvie inc.]

These highlights do not include all the information needed to use Moderiba (ribavirin, USP) safely and effectively. See full prescribing information for Moderiba (ribavirin, USP). Moderiba (ribavirin, USP) Tablets for oral useInitial U.S. Approval: 2002

Tridione [abbvie inc.]

TRIDIONE® (trimethadione)Tablets

Zemplar [abbvie inc.]

These highlights do not include all the information needed to use ZEMPLAR safely and effectively. See full prescribing information for ZEMPLAR. ZEMPLAR (paricalcitol) capsules, for oral use Initial U.S. Approval: 1998

Venclexta [abbvie inc.]

These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA. VENCLEXTA (venetoclax tablets) for oral use Initial U.S. Approval: 2016

Xerese [valeant pharmaceuticals north america llc]

These highlights do not include all the information needed to use XERESE safely and effectively. See full prescribing information for XERESE. XERESE (acyclovir and hydrocortisone) cream, for topical use Initial U.S. Approval: 2009

Sodium chromate 51 [anazaohealth corporation]

Sodium Chromate 51

K-tab [remedyrepack inc.]

K-TAB® (potassium chloride extended-release tablets, USP)

Survanta [abbvie inc.]

SURVANTA

Humira [abbvie inc.]

These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA (adalimumab) injection, for subcutaneous useInitial U.S. Approval: 2002

K-tab [aphena pharma solutions - tennessee, llc]

K-TAB®(potassium chloride extended-release tablets, USP)

Folotyn [allos therapeutics]

These highlights do not include all the information needed to use FOLOTYN safely and effectively. See full prescribing information for FOLOTYN.FOLOTYN (pralatrexate injection), for intravenous use Initial U.S. Approval: 2009

Enalapril maleate [stat rx usa llc]

NA

Enalapril maleate [state of florida doh central pharmacy]

NA

Enalapril maleate [ncs healthcare of ky, inc dba vangard labs]

Enalapril Maleate

Zemplar [abbvie inc.]

These highlights do not include all the information needed to use ZEMPLAR safely and effectively. See full prescribing information for ZEMPLAR. ZEMPLAR (paricalcitol) injection, for intravenous useInitial U.S. Approval: 1998

Trilipix [abbvie inc.]

These highlights do not include all the information needed to use TRILIPIX safely and effectively. See full prescribing information for TRILIPIX. TRILIPIX (fenofibric acid) capsule, delayed release for oral useInitial U.S. Approval: 2008



Advertisement
Quick Search
Advertisement
Advertisement